PSMA、GRPR PET/CT与mpMRI对原发性前列腺癌局部分期的头对头比较及预后价值
该回顾性研究纳入81例中高危前列腺癌患者,在根治性前列腺切除术前进行mpMRI、[68Ga]Ga-PSMA-617 PET/CT和[68Ga]Ga-RM26 GRPR PET/CT,并与全mount病理对照。PSMA PET/CT总体准确性高于GRPR PET/CT,联合mpMRI可提高分期准确性并独立预测生化复发。
要点
- PSMA PET/CT总体准确性56%,高于GRPR PET/CT的36%(P=0.011)。
- PSMA PET/CT联合mpMRI较单用mpMRI提高分期准确性(61% vs 41%,P=0.002)。
- PSMA PET/CT联合mpMRI诊断T3a及以上是生化复发独立预测因子(HR 4.277,P<0.001)。
核心结论
- PSMA PET/CT联合mpMRI在原发性前列腺癌局部分期准确性上优于单用mpMRI,并提供超越常规临床病理参数的增量预后价值。
研究设计与样本
- 回顾性分析纳入81例中危或高危前列腺癌患者,根治性前列腺切除术前接受mpMRI、[68Ga]Ga-PSMA-617 PET/CT和[68Ga]Ga-RM26 GRPR PET/CT,影像与全mount病理对照。
主要发现
- PSMA PET/CT总体准确性56%,高于GRPR PET/CT的36%(P=0.011)。
- PSMA PET/CT双侧前列腺内病变检出率72%,高于mpMRI的54%(P=0.024)。
- 纯腺泡腺癌亚组中,PSMA PET/CT总体准确性58%,高于mpMRI的39%(P=0.029)和GRPR PET/CT的34%(P=0.005)。
- PSMA PET/CT联合mpMRI总体准确性61%,高于单用mpMRI的41%(P=0.002)。
- PSMA PET/CT联合mpMRI诊断T3a及以上是生化复发无生存的独立预测因子(HR 4.277,P<0.001)。
关键数值与推荐
- PSMA PET/CT总体准确性56% vs GRPR PET/CT 36%(P=0.011)。
- PSMA PET/CT双侧病变检出72% vs mpMRI 54%(P=0.024)。
- 纯腺泡腺癌亚组PSMA PET/CT 58% vs mpMRI 39%(P=0.029)和GRPR PET/CT 34%(P=0.005)。
- PSMA PET/CT联合mpMRI 61% vs 单用mpMRI 41%(P=0.002)。
- PSMA PET/CT联合mpMRI诊断T3a及以上预测生化复发无生存的HR为4.277(P<0.001)。
临床怎么用
- 对中高危原发性前列腺癌,可考虑PSMA PET/CT联合mpMRI进行局部分期以优化风险分层。
- 联合影像提示T3a及以上有助于识别生化复发高风险患者,辅助手术或局灶治疗决策。
局限性
- 回顾性分析,样本量81例,结论需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Accurate local staging of primary prostate cancer (PCa) is crucial for guiding therapeutic strategies. Current imaging methods, including MRI and PET/CT, may have variable accuracy in detecting key disease features. This head-to-head study compared the diagnostic performance of prostate-specific membrane antigen (PSMA), gastrin-releasing peptide receptor (GRPR) PET/CT, multiparametric MRI (mpMRI), and combined PET/CT plus MRI for local staging of intermediate-risk and high-risk PCa, along with their prognostic significance. Methods: In this retrospective analysis, patients with intermediate-risk or high-risk PCa underwent mpMRI, [68Ga]Ga-PSMA-617 PET/CT, and [68Ga]Ga-RM26 (GRPR-targeted) PET/CT before radical prostatectomy. Imaging findings were compared with whole-mount histopathology for local T stage, bilateral intraprostatic disease, extraprostatic extension, and seminal vesicle invasion. The prognostic value for predicting biochemical recurrence-free survival was assessed. Results: Among 81 eligible men, PSMA PET/CT showed higher overall accuracy than GRPR PET/CT (56% vs. 36%, P = 0.011) and improved detection of bilateral intraprostatic disease compared with mpMRI (72% vs. 54%, P = 0.024). In the pure acinar adenocarcinoma subgroup, PSMA PET/CT outperformed both mpMRI and GRPR PET/CT for overall accuracy (58% vs. 39% and 34%, P = 0.029 and 0.005, respectively). The combined PSMA PET/CT plus mpMRI further enhanced staging accuracy compared with mpMRI alone (61% vs. 41%, P = 0.002). Additionally, a local stage T3a or greater based on PSMA PET/CT plus mpMRI was an independent predictor of biochemical recurrence-free survival (hazard ratio, 4.277; P < 0.001), surpassing conventional clinicopathologic factors. Conclusion: PSMA PET/CT, especially when combined with mpMRI, offers superior accuracy in local staging and provides incremental prognostic value beyond standard clinicopathological parameters. Incorporating PET/MRI-derived local staging into clinical decision-making may improve patient stratification, guide surgical or focal therapy strategies, and ultimately enhance patient outcomes.
引用
- Li Y, Yang J, Chen B, et al. Head-to-Head Comparison of mpMRI, PSMA, GRPR PET/CT, and PET/CT Plus MRI for Local Staging of Primary Prostate Cancer and Their Prognostic Value. J Nucl Med. 2026. PMID: 41611483. doi:10.2967/jnumed.125.271410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。